Welcome to the summer 2016 edition of European Oncology & Haematology, We are delighted to share this new selection of timely reviews and editorials across a variety of oncology and haematology topics.
In this edition Maurice Pérol discusses the two revolutions in the treatment of advanced non-small cell lung cancer and Christos Sotiriou and colleagues discuss genomic drivers in breast cancers. Ana Oaknin and Victor Rodriguez-Freixinos explore the timely topic of bevacizumab in the treatment of cervical cancer and Maria-Domenica Cappellini and colleagues review the 10 year anniversary of the Sherlock Holmes Symposia.
We hope you enjoy this edition of European Oncology & Haematology and that it provides a useful information relevant to your practice and interests.
Foreword – European Oncology & Haematology, 2016;12(1):
Welcome to the latest edition of European Oncology & Haematology, which features a wide variety of topical articles of interest to oncologists and haematologists as well as the wider medical community. We begin with a review by Pérol of the treatment of advanced non-small cell lung cancer (NSCLC). Thanks to the advances in therapies that […]
The Two Revolutions in the Treatment of Advanced Non-small Cell Lung Cancer
Changes that have been occurring since approximately 10 years in the treatment of advanced non-small cell lung cancer (NSCLC) constitute a good illustration of the evolving paradigms in oncology. Ten years ago, advanced NSCLC was considered as a single entity, resulting from tumour cells proliferation and was therefore treated with cytotoxic drugs. With this approach, […]
Developments in Advanced Prostate Cancer in 2016
In the field of detection and imaging, multiparametric-prostate magnetic resonance images (MP-MRI) were re-interpreted with the Prostate Imaging Reporting and Data System (PIRADS) V.2 and correlated with the eventual histo-pathological finding(s) in 68 patients undergoing either transrectal ultrasound (TRUS)-guided biopsy or radical prostatectomy after the MP-MRI. The findings of this study suggest that a PIRADS […]
To Hyperfractionate or not to Hyperfractionate – Is it Really a Question?
The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical […]
Is Knowledge Better than Ignorance in Paediatric Oncogenetics? Identifying Biological Causes and Searching for Meaning
The rate of childhood cancer caused by a genetic predisposition is now estimated around 8.5%.1 While proposing a genetic counselling has been classically considered as part of good clinical practice for few malignancies (retinoblastoma, adrenocortical tumours, choroid plexus carcinoma), its actual requirement and relevance was for long deemed questionable for most paediatric cancers. However, next […]
Supporting Older People with Cancer – Merging Geriatric and Oncological Knowledge
It is well known that there is a demographic transition all over the world. The most important explanation to this is the change from previously large groups of children in a family to now commonly only one or two children in most countries. This decrease in birth giving together with improved longevity means that most […]
Supportive Care of Patients Undergoing Immunotherapy
Programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are immune checkpoints that are expressed on the surface of antigen-presenting cells in the initiator and effector phase of T-cell activation respectively. They are responsible for “switching off” the T-cell. Inhibition of these checkpoints allows for overexpression of the immune system. The mechanism of defeating […]
Genomic Drivers in Breast Cancers
Significant advances in next-generation sequencing (NGS) technologies have allowed the identification of alterations in cancer genomes of different tumour types, providing important insight into the genetic complexity of cancers including breast cancer (BC). Notably, we have learned that primary BC genomes harbour mutations in multiple cancer genes but at a low frequency, less than 5% […]
Bevacizumab in the Treatment of Cervical Cancer – Current Evidence and Next Steps
Worldwide, cervical cancer is the fourth most common cancer in women and seventh most common cancer overall. In 2012, approximately 528,000 new cervical cancer cases were diagnosed globally. Cervical cancer accounted for 7.5% of all female cancer deaths with approximately 266,000 deaths; the majority (87%) of these deaths occurred in developing countries.1,2 In Europe, the […]
Therapeutic Place of Fulvestrant in the Management of Hormone-receptor Positive Breast Cancer
Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women.1 More than 1.67 million cases of breast cancer were recorded in 2012, accounting for around 11.9% of all new cancer cases and 25.1% in women.2 Oestrogen receptor- (ER)-positive breast cancer accounts for 75% of breast cancers in […]
Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review
Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]
Investigating Rare Haematological Disorders – A Celebration of 10 Years of the Sherlock Holmes Symposia
Early diagnosis of rare haematological diseases Rare haematological diseases often present ‘in disguise’, with nonspecific symptoms such as pancytopaenia, decreased circulating levels of one or two cell subsets and splenomegaly. Gaucher disease (GD) provides an excellent paradigm when considering challenges in diagnosing rare haematological diseases. Individuals presenting with GD will only rarely be seen regularly […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!